TROY, Mich., May 07, 2026 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the first quarter of 2026.Q1 revenue of $1.0 billion, reflects notable improvement in the year-over-year performance versus the prior quarter driven by strength in the ETM segment, down 10.7% year-over-year; underlying revenue excluding previously disclosed discrete items down approximately 3.3% year-over-year, which improved 60 basis points versus the prior quarter Q1 adjusted SG&A decline of 10.3% reflects the third straight quarter of year-over-year reduction of approximately 10% or more and continued momentum on structural and demand-driven expense optimization initiatives Q1 operating loss of $5.1 million; $4.1 million of operating earnings on an adjusted basis Q1 adjusted...

BALTIMORE, May 07, 2026 (GLOBE NEWSWIRE) — MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for first quarter 2026.(1) First Quarter 2026 Highlights(1)Paid Subscribers returned to growth in first quarter 2026 following stabilization in the second half of 2025, reflecting improved customer acquisition and retention. Paid Subscribers were 381 thousand as of March 31, 2026, compared with 374 thousand as of December 31, 2025. Active Free subscribers were 2.0 million as of March 31, 2026. Total Net Revenue was $77.0 million in the first quarter 2026(2)Billings for first quarter 2026 totaled $81.4 million, representing a...

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK) today announced its financial results for the period ended March 31, 2026. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. FINANCIAL SUMMARYBook Value per Share (BVpS): $16.57, compared to $15.35 as at December 31, 2025 (+8% increase) Total Book Value: $227 millionThe increase in Book Value during the quarter was primarily driven by valuation growth across core portfolio holdings in SpaceX and OpenAI. PORTFOLIO COMPANY HIGHLIGHTS SpaceXRecently valued at approximately US$1 trillion in connection with the merger with xAI, further reinforcing its position as one of the world’s most valuable and strategically important private technology companies. OpenAIDuring the quarter, OpenAI completed...

— Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit — — Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026, as well as ELEVATE-44-201 open-label period and Cohort 2 data by year-end 2026 — — Cash runway expected into Q3 2027 with $255 million in cash, cash equivalents and marketable securities as of March 31, 2026 — — Entrada to host investor webcast and conference call today, Thursday, May 7, at 8:30 a.m. ET — BOSTON, May 07, 2026 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the first quarter ended March 31, 2026, and highlighted recent business updates. “With the recently announced positive data from Cohort...

Net Revenue of $65.5 million and Gross Profit Margin of 52.8% for Q1 2026 Q1 2026 Net Cash Provided from Continuing Operations of $8.7 million, representing 13.3% Operating Cash Flow Yield1 Q1 2026 Free Cash Flow1 of $7.8 million, representing 10.3% Free Cash Flow Yield1 15th Consecutive Quarter of Positive Cash Flow from Continuing Operations and 11th Consecutive Quarter of Positive Free Cash Flow1 TORONTO, May 07, 2026 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today reported its financial results for the first quarter ended March 31, 2026. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise. The following financial...

CompoSecure delivers record ROS-driven results Husky impacted by unexpected market headwinds due to oil and resin price shock and continued tariff uncertainty ROS deployment accelerating across the enterpriseFirst Quarter HighlightsResults compared to prior year period unless otherwise noted; pro forma metrics inclusive of Husky Technologies for full quarter.   Pro Forma Adjusted Net Sales of $421.2 million, up 3% GAAP Net Loss of $235.0 million Pro Forma Adj. EBITDA of $82.1 million, down 16%, and Pro Forma Adj. EBITDA margin of 19.5%, down 430 bpsSecond Quarter 2026 OutlookFollowing quarterly guidance is based upon expectations for the combined results of CompoSecure and Husky Technologies.Adjusted Net Sales of $425 to $475 million Adjusted EBITDA of $105 to $120 millionFull Year 2026 OutlookFollowing annual guidance is based...

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) — Resolute Holdings Management, Inc. (“Resolute Holdings”) (NYSE: RHLD), an operating management company responsible for providing management services to the operating businesses of GPGI, Inc. (“GPGI”) (NYSE: GPGI), today reported financial results for its fiscal first quarter ended March 31, 2026. Resolute Holdings reported first quarter earnings per share attributable to common stockholders of $7.19 compared to ($0.39) in the prior year and Non-GAAP Fee-Related Earnings per share of $0.69 compared to ($0.07) in the prior year. The increase in Non-GAAP profitability was driven by the higher fee stream as a result of the execution of the management agreement with Husky Holdings LLC (“Husky Holdings”) in January 2026, along with organic growth in fees from the CompoSecure management agreement....

Cloud subscriptions revenue increased 25% year-over-year to $124.5 million, while cash flow provided by operations totaled $48.8 million MCLEAN, Va., May 07, 2026 (GLOBE NEWSWIRE) — Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights:Revenue: Cloud subscriptions revenue was $124.5 million, up 25% compared to the first quarter of 2025. Total subscriptions revenue, which includes sales of our cloud subscriptions, other subscriptions, and the related maintenance and support, increased 19% year-over-year to $160.3 million. Professional services revenue was $41.9 million, an increase of 31% compared to the first quarter of 2025. Total revenue was $202.2 million, up 21% compared to the first quarter of 2025. Cloud net annualized recurring revenue...

Q1 revenue increased 36% year-over-year to a record $205 million, driven by robust marketplace growth. Q1 marketplace revenue growth accelerated to 40% year-over-year, driven by expanding networks of buyers and suppliers and increasing wallet share. Q1 gross profit increased 39% year-over-year to a record $78.5 million, driven by strong marketplace growth and marketplace gross margin expansion. Q1 Adjusted EBITDA improved $10.4 million year-over-year to Adjusted EBITDA of $10.5 million, driven by expanding marketplace gross margin and strong operating expense leverage. Announced a new strategic partnership with Siemens, to embed Xometry’s proprietary manufacturability, pricing, sourcing and execution intelligence directly within Siemens Xcelerator. Siemens is purchasing approximately $50 million of Xometry Class A common stock, underscoring...

1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “We are accelerating the adoption and commercial expansion for Amtagvi after record high demand. Iovance is well positioned through 2026 for long-term revenue growth,...